GenevationsUS LLP
Genevation LTD is a pioneering company in personalized cancer vaccines, utilizing AI-driven, cell-free vaccine technology to develop rapid, tailored mRNA cancer vaccines. Founded in 2022 in London, the company aims to revolutionize cancer care through innovative science and technology, focusing on precision oncology and expanding its pipeline to various cancer types.
Industries
Nr. of Employees
small (1-50)
GenevationsUS LLP
Stevenage, Herefordshire, United Kingdom, Europe
Products
Personalized mRNA cancer vaccine candidates
Therapeutic and prophylactic mRNA vaccine candidates designed from patient-specific neoantigens, with stated development focus on lung, colon, and skin cancers.
Personalized mRNA cancer vaccine candidates
Therapeutic and prophylactic mRNA vaccine candidates designed from patient-specific neoantigens, with stated development focus on lung, colon, and skin cancers.
Services
Neoantigen discovery and personalized vaccine design
End-to-end identification of tumor-specific neoantigens from patient samples and design of personalized mRNA vaccine candidates using AI and genomic analysis.
Preclinical development and in vivo testing
Design and execution of preclinical efficacy studies in mice for vaccine candidates as part of progression to clinical evaluation.
mRNA candidate manufacturing (cell-free)
Production of mRNA vaccine candidates using a cell-free manufacturing approach suitable for rapid iteration in early development.
Neoantigen discovery and personalized vaccine design
End-to-end identification of tumor-specific neoantigens from patient samples and design of personalized mRNA vaccine candidates using AI and genomic analysis.
Preclinical development and in vivo testing
Design and execution of preclinical efficacy studies in mice for vaccine candidates as part of progression to clinical evaluation.
mRNA candidate manufacturing (cell-free)
Production of mRNA vaccine candidates using a cell-free manufacturing approach suitable for rapid iteration in early development.
Expertise Areas
- Personalized cancer vaccines
- Neoantigen discovery and prioritization
- mRNA therapeutics and IVT
- Cell-free manufacturing
Key Technologies
- mRNA therapeutics
- AI-driven neoantigen prediction
- Next-generation sequencing (NGS)
- Cell-free manufacturing